BR0300521A - Process for obtaining stable isotonic injectable solution of predefined glucose diluted gatifloxacin, stable injectable solution of predifined glucose diluted gatifloxacin, closed-loop packaging process of the obtained injectable solution, use of closed system for packaging solution of injectable gatifloxacin, use of the prediluted glucose-diluted gatifloxacin solution for injection and method of administration - Google Patents

Process for obtaining stable isotonic injectable solution of predefined glucose diluted gatifloxacin, stable injectable solution of predifined glucose diluted gatifloxacin, closed-loop packaging process of the obtained injectable solution, use of closed system for packaging solution of injectable gatifloxacin, use of the prediluted glucose-diluted gatifloxacin solution for injection and method of administration

Info

Publication number
BR0300521A
BR0300521A BR0300521A BR0300521A BR0300521A BR 0300521 A BR0300521 A BR 0300521A BR 0300521 A BR0300521 A BR 0300521A BR 0300521 A BR0300521 A BR 0300521A BR 0300521 A BR0300521 A BR 0300521A
Authority
BR
Brazil
Prior art keywords
gatifloxacin
solution
injectable
glucose
diluted
Prior art date
Application number
BR0300521A
Other languages
Portuguese (pt)
Inventor
Heno Jacomo Perillo
Original Assignee
Halex Star Ind Farmaceutica Lt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halex Star Ind Farmaceutica Lt filed Critical Halex Star Ind Farmaceutica Lt
Priority to BR0300521A priority Critical patent/BR0300521A/en
Priority to PCT/BR2004/000030 priority patent/WO2004080371A2/en
Publication of BR0300521A publication Critical patent/BR0300521A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Molecular Biology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"PROCESSO DE OBTENçãO DE SOLUçãO ISOTÈNICA INJETáVEL ESTáVEL DE GATIFLOXACINA PRé-DILUìDA EM GLICOSE, SOLUçãO INJETáVEL ESTáVEL DE GATIFLOXACINA PRé-DILUìDA EM GLICOSE, PROCESSO DE ACONDICIONAMENTO EM SISTEMA FECHADO DA SOLUçãO INJETáVEL OBTIDA, USO DE SISTEMA FECHADO PARA ACONDICIONAMENTO DE SOLUçãO INJETáVEL DE GATIFLOXACINA, USO DA SOLUçãO INJETáVEL A BASE DE GATIFLOXACINA PRé-DILUìDA EM GLICOSE, OBTIDA E MéTODO DE ADMINISTRAçãO". A presente invenção tem como premissa que o uso de preparações pré-diluídas em sistema fechado diminui os riscos de erros na administração de medicamentos, diminuindo as etapas de manuseio do medicamento pela equipe de enfermagem do hospital, além de reduzir os riscos de contaminação. O produto obtido pela presente invenção apresenta-se na forma de solução injetável de gatifloxacina pré-diluída em glicose, acondicionada em bolsa plástica flexível de trilaminado (sistema fechado). Através da formulação pré-diluída em glicose e do sistema fechado, evita-se os riscos de contaminação através do ar ou por contato durante administração. A formulação é acrescida de glicose 5%, uma solução isotónica, onde a gatifloxacina"PROCEDURE FOR OBTAINING INJECTABLE SOLUTE DETECTED INJECTABLE FIXED SOLUTIONS FOR INJECTED FIXED SOLUTE SYSTEMS, INJECTABLE SOLUTE INJECTABLE FIXED SOLUTIONS , USE OF THE INJECTABLE SOLUTION OF PREDILUTED GLUCOSE GAIFLOXACINE, OBTAINED AND METHOD OF ADMINISTRATION ". The present invention is based on the premise that the use of pre-diluted preparations in a closed system reduces the risks of medication administration errors, reducing the medication handling steps by the hospital nursing staff, as well as reducing the risks of contamination. The product obtained by the present invention is in the form of a glucose-prediluted gatifloxacin solution for injection in a flexible trilaminated plastic pouch (closed system). Pre-diluted glucose formulation and closed system avoids the risk of contamination through air or contact during administration. The formulation is added 5% glucose, an isotonic solution, where gatifloxacin

BR0300521A 2003-03-13 2003-03-13 Process for obtaining stable isotonic injectable solution of predefined glucose diluted gatifloxacin, stable injectable solution of predifined glucose diluted gatifloxacin, closed-loop packaging process of the obtained injectable solution, use of closed system for packaging solution of injectable gatifloxacin, use of the prediluted glucose-diluted gatifloxacin solution for injection and method of administration BR0300521A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR0300521A BR0300521A (en) 2003-03-13 2003-03-13 Process for obtaining stable isotonic injectable solution of predefined glucose diluted gatifloxacin, stable injectable solution of predifined glucose diluted gatifloxacin, closed-loop packaging process of the obtained injectable solution, use of closed system for packaging solution of injectable gatifloxacin, use of the prediluted glucose-diluted gatifloxacin solution for injection and method of administration
PCT/BR2004/000030 WO2004080371A2 (en) 2003-03-13 2004-03-15 Injectable isotonic solution of gatifloxacin pre-diluted in glucose.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR0300521A BR0300521A (en) 2003-03-13 2003-03-13 Process for obtaining stable isotonic injectable solution of predefined glucose diluted gatifloxacin, stable injectable solution of predifined glucose diluted gatifloxacin, closed-loop packaging process of the obtained injectable solution, use of closed system for packaging solution of injectable gatifloxacin, use of the prediluted glucose-diluted gatifloxacin solution for injection and method of administration

Publications (1)

Publication Number Publication Date
BR0300521A true BR0300521A (en) 2005-03-22

Family

ID=32968093

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0300521A BR0300521A (en) 2003-03-13 2003-03-13 Process for obtaining stable isotonic injectable solution of predefined glucose diluted gatifloxacin, stable injectable solution of predifined glucose diluted gatifloxacin, closed-loop packaging process of the obtained injectable solution, use of closed system for packaging solution of injectable gatifloxacin, use of the prediluted glucose-diluted gatifloxacin solution for injection and method of administration

Country Status (2)

Country Link
BR (1) BR0300521A (en)
WO (1) WO2004080371A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210686A (en) * 1978-06-19 1980-07-01 Baxter Travenol Laboratories Inc. Multi-layered plastic sheeting having high clarity, strength, and resistance to water vapor transmission
TWI287987B (en) * 2000-08-14 2007-10-11 Senju Pharma Co Cytokine inhibitor

Also Published As

Publication number Publication date
WO2004080371A2 (en) 2004-09-23
WO2004080371A3 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
Malik et al. Maximising application of the aerosol box in protecting healthcare workers during the COVID‐19 pandemic
DK1919432T3 (en) Liquid Medication Transfer Devices for Safe Safe Resting Connection on Medical Vials
BRPI0415470A (en) aqueous aerosol preparation
BR0316738A (en) Device for controlling the collection and administration of substances to a patient, blood processing system and method for controlling blood transfer between a patient and a blood treatment unit.
BR0215480A (en) medication delivery system
BRPI0511611A (en) medical device configuration based on identification information recognition
ES2537294T3 (en) Gemcitabine solution ready to be infused
BRPI0616127B1 (en) Aqueous, sterile, stable, injectable pharmaceutical solution and its method of preparation
Donnelly Stability of diluted ketamine packaged in glass vials
BRPI0414321B8 (en) high pressure sterilization for final sterilization of pharmaceutical preparations and medical products
BR0300521A (en) Process for obtaining stable isotonic injectable solution of predefined glucose diluted gatifloxacin, stable injectable solution of predifined glucose diluted gatifloxacin, closed-loop packaging process of the obtained injectable solution, use of closed system for packaging solution of injectable gatifloxacin, use of the prediluted glucose-diluted gatifloxacin solution for injection and method of administration
BR112014015605A2 (en) reconstitution method for high concentration dry protein formulations
BRPI0407051A (en) Air conveying device for plastic containers equipped with a projecting collar
Sehgal et al. Barrier protection during airway intubation
CN205434526U (en) Disposable operating room venous transfusion package
Callejas et al. 3PC-013 Pharmaceutical compounding in paediatric patch testing: are we sure about the actual active ingredient concentration?
CN204709187U (en) A kind of first aid stretcher
US20190336443A1 (en) Ready-To-Use Liquid Parenteral Formulations Of Ribavirin
ES2146200T3 (en) PERITONEALLY INDUCED DRUGS.
US20230166025A1 (en) Single use disposable time indication devices
US11883532B2 (en) Pharmaceutical compositions for parenteral administration comprising ibuprofen and a phosphate buffer
Krämer et al. Good handling practice of parenterally administered medicines in neonatal intensive care units–position paper of an interdisciplinary working group
CN204520978U (en) A kind of joint puncture bag
CN207089958U (en) Medicament suction plastic internal support
Ludeña et al. Use of the Magill forceps as an aid for i-gel® removal after endotracheal intubation: A safe and simple technique

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: BASEADO NO ART. 216 1 DA LPI, APRESENTE COPIA AUTENTICADA DA PROCURACAO PARA QUE ESTA SEJA ACEITA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2038 DE 26/01/2010.